235 related articles for article (PubMed ID: 12195692)
1. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Weitz IC; Israel VK; Waisman JR; Presant CA; Rochanda L; Liebman HA
Thromb Haemost; 2002 Aug; 88(2):213-20. PubMed ID: 12195692
[TBL] [Abstract][Full Text] [Related]
2. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
[TBL] [Abstract][Full Text] [Related]
3. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
Stricker H; Marchetti O; Haeberli A; Mombelli G
Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
[TBL] [Abstract][Full Text] [Related]
5. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial.
Falanga A; Levine MN; Consonni R; Gritti G; Delaini F; Oldani E; Julian JA; Barbui T
Thromb Haemost; 1998 Jan; 79(1):23-7. PubMed ID: 9459316
[TBL] [Abstract][Full Text] [Related]
6. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. The DVTENOX Study Group.
Thromb Haemost; 1993 Dec; 70(6):909-14. PubMed ID: 8165610
[TBL] [Abstract][Full Text] [Related]
7. Increased hemostatic molecular markers in patients undergoing anticoagulant therapy.
Wada H; Ikuma H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Onoda K; Yamada N; Ohta T; Nishioka J; Sakuragawa N; Shiku H
Semin Thromb Hemost; 2000; 26(1):113-8. PubMed ID: 10805292
[TBL] [Abstract][Full Text] [Related]
8. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
Kakkar AK; Levine MN; Kadziola Z; Lemoine NR; Low V; Patel HK; Rustin G; Thomas M; Quigley M; Williamson RC
J Clin Oncol; 2004 May; 22(10):1944-8. PubMed ID: 15143088
[TBL] [Abstract][Full Text] [Related]
10. Coagulation and fibrinolytic profiles and appropriate use of heparin after living-donor liver transplantation.
Kaneko J; Sugawara Y; Tamura S; Togashi J; Matsui Y; Akamatsu N; Kishi Y; Makuuchi M
Clin Transplant; 2005 Dec; 19(6):804-9. PubMed ID: 16313329
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
12. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
Bombeli T; Raddatz-Mueller P; Fehr J
Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
[TBL] [Abstract][Full Text] [Related]
13. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.
Mukherjee SD; Swystun LL; Mackman N; Wang JG; Pond G; Levine MN; Liaw PC
Pathophysiol Haemost Thromb; 2010; 37(2-4):88-97. PubMed ID: 21430357
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats.
Harada N; Okajima K; Uchiba M
Crit Care Med; 2006 Jul; 34(7):1883-91. PubMed ID: 16641616
[TBL] [Abstract][Full Text] [Related]
15. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
Eisses MJ; Velan T; Aldea GS; Chandler WL
Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
[TBL] [Abstract][Full Text] [Related]
16. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.
Peternel P; Terbizan M; Tratar G; Bozic M; Horvat D; Salobir B; Stegnar M
Thromb Res; 2002 Feb; 105(3):241-6. PubMed ID: 11927130
[TBL] [Abstract][Full Text] [Related]
17. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.
de Raucourt E; Meyer G; Landais P; Gouaref Z; Morinet P; Monge F; Sors H; Fischer AM
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):249-53. PubMed ID: 10870805
[TBL] [Abstract][Full Text] [Related]
18. D-dimers, thrombin-antithrombin complexes, and risk factors for thromboembolism in hospitalized patient.
Pottier P; Fouassier M; Hardouin JB; Volteau C; Planchon B
Clin Appl Thromb Hemost; 2009 Dec; 15(6):666-75. PubMed ID: 18796458
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Ernofsson M; Strekerud F; Toss H; Abildgaard U; Wallentin L; Siegbahn A
Thromb Haemost; 1998 Mar; 79(3):491-4. PubMed ID: 9531028
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers.
Bombeli T; Raddatz Mueller P; Fehr J
Haemostasis; 2001; 31(2):90-8. PubMed ID: 11684864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
